Shore Capital Reiterates “Buy” Rating for Shire PLC (SHP)
Shire PLC (LON:SHP)‘s stock had its “buy” rating reiterated by research analysts at Shore Capital in a research report issued to clients and investors on Wednesday.
SHP has been the subject of a number of other research reports. HSBC Holdings plc upgraded Shire PLC to a “hold” rating and set a GBX 4,450 ($60.00) target price for the company in a report on Thursday, July 6th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Shire PLC in a report on Friday, July 7th. J P Morgan Chase & Co reiterated an “overweight” rating and issued a GBX 6,000 ($80.90) target price on shares of Shire PLC in a report on Tuesday, July 11th. Deutsche Bank AG dropped their target price on Shire PLC from GBX 6,100 ($82.24) to GBX 6,000 ($80.90) and set a “buy” rating for the company in a report on Tuesday, June 13th. Finally, Liberum Capital reiterated a “hold” rating and issued a GBX 4,900 ($66.06) target price on shares of Shire PLC in a report on Wednesday, June 21st. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of GBX 5,837.29 ($78.70).
Shares of Shire PLC (LON:SHP) opened at 3824.50 on Wednesday. The company’s market cap is GBX 34.67 billion. The firm has a 50-day moving average price of GBX 3,912.51 and a 200 day moving average price of GBX 4,376.95. Shire PLC has a 12 month low of GBX 3,603.50 and a 12 month high of GBX 5,377.00.
In other news, insider Dominic Blakemore bought 152 shares of the firm’s stock in a transaction on Friday, June 30th. The stock was acquired at an average cost of GBX 4,255 ($57.37) per share, with a total value of £6,467.60 ($8,719.97). Also, insider Flemming Ornskov bought 8,400 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The shares were purchased at an average cost of GBX 3,665 ($49.41) per share, with a total value of £307,860 ($415,073.48).
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.